Showing results (901-910 of 5,009) with videos related to
Sort By:
Pageof 501
American Journal of Clinical Oncology|April 1, 1991
Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Final report by the Radiation Therapy Oncology GroupC A Perez, T Pajak, B Emami, et al.American Journal of Clinical Oncology|February 1, 1991
A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancerD T Ransom, D Neuberg, C L Loprinzi, et al.American Journal of Clinical Oncology|June 7, 2007
Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field techniqueAndy W Su, Ashesh B JaniAmerican Journal of Clinical Oncology|June 7, 2007
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancerRonald Bukowski, David Cella, Kathleen Gondek, et al.American Journal of Clinical Oncology|June 7, 2007
Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatmentMin Yao, Pifu Luo, Henry T Hoffman, et al.American Journal of Clinical Oncology|June 7, 2007
A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanomaSvetomir N Markovic, Vera J Suman, Ravi A Rao, et al.American Journal of Clinical Oncology|June 7, 2007
Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancerSerap Akyurek, Eric L Chang, Anita Mahajan, et al.American Journal of Clinical Oncology|February 6, 2009
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumorsWilliam N William, Joseph L Lee, Dong M Shin, et al.American Journal of Clinical Oncology|February 6, 2009
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trialPaula P Lajolo, Beatriz de Camargo, Auro del GiglioAmerican Journal of Clinical Oncology|February 6, 2009
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancerAnna Novarino, Maria Antonietta Satolli, Isabella Chiappino, et al.Pageof 501